D. Cole

B. Rosen, H. Risch, S. Narod, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Short Communication The N314D Polymorphism of Galactose-1-Phosphate Uridyl Transferase Does Not Modify the Risk of Ovarian Cancer

B. Rosen, H. Risch, S. Narod, 2003 .

The N 314 D Polymorphism of Galactose-1-Phosphate Uridyl Transferase Does Not Modify the Risk of Ovarian Cancer

B. Rosen, H. Risch, S. Narod, 2003 .

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

B. Rosen, L. Bradley, H. Risch, 2001, American journal of human genetics.

A genetic epidemiological study of carcinoma of the fallopian tube.

B. Rosen, S. Narod, J. McLaughlin, 2001, Gynecologic oncology.

Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.

S. Verma, G. Dranitsaris, M. Clemons, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Linkage analysis of 26 Canadian breast and breast-ovarian cancer families

N. Boyd, P. Tonin, J. Simard, 1995, Human Genetics.

Re: Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations.

C. Marcocci, F. Cetani, M. Bisceglia, 2008, Surgery.

Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.

G. Dranitsaris, M. Clemons, D. Cole, 2006, The oncologist.

Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer.

D B Plewes, E Ramsay, M. Yaffe, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of Breast Magnet ic Resonance Imaging , Mammography , and Ultrasound for Surve i l lance of Women at High Risk for Heredi tary Breast Cancer

D. Plewes, E. Warner, S. Narod, 2001 .

Assessment of therapeutic response in patients with metastatic bone disease.

M. Clemons, A. Clamp, S. Danson, 2004, The Lancet. Oncology.

Can bone markers guide more effective treatment of bone metastases from breast cancer?

M. Clemons, D. Cole, M. C. Gainford, 2006, Breast Cancer Research and Treatment.

Psychological adjustment to familial genetic risk assessment: differences in two longitudinal samples.

B. Rosen, P. Ritvo, R. Styra, 2000, Patient education and counseling.

The role of urinary N-telopeptides in evaluating the palliative benefit of bisphosphonates in metastatic breast cancer

G. Dranitsaris, M. Clemons, C. Simmons, 2007 .

Screening for multiple endocrine neoplasia type 2A with DNA-polymorphism analysis.

P. Goodfellow, Z. Pausova, S. Narod, 1992, Henry Ford Hospital medical journal.

A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy

G. Dranitsaris, M. Clemons, D. Cole, 2008, Breast Cancer Research and Treatment.

A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D3 in breast cancer patients with bone metastases

G. Dranitsaris, M. Clemons, R. Vieth, 2010, Cancer.